Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension

Journal of Human Hypertension

Volumn 24, Issue 4, 2010, Pages 263-273

  Kjeldsen, S E ^a   Stlhammar, J ^b   Hasvold, P ^c   Bodegard, J ^c   Olsson, U ^d   Russell, D ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d STATISTICON AB   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Blood pressure; Cardiovascular diseases; Epidemiology; Heart failure

Indexed keywords

CANDESARTAN; LOSARTAN;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK REDUCTION;

EID: 77949875945     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.77     Document Type: Article

References (32)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371(9623): 1513-1518.
2. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-592.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
4. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
5. Gavras H. Update on the clinical pharmacology of candesartan cilexetil. Am J Hypertens 2000; 13(1 Pt 2): 25S-30S.
6. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-1559.
7. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110(17): 2618-2626.
8. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875-886.
9. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21(8): 1563-1574.
10. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302(2): 237-243.
11. Fabiani ME, Dinh DT, Nassis L, Casley DJ, Johnston CI. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. Am J Hypertens 2000; 13(9): 1005-1013.
12. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319(1): 137-146.
13. Stanley K. Design of randomized controlled trials. Circulation 2007; 115(9): 1164-1169.
14. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008; 118(12): 1294-1303.
15. Bjørkenstam C. The Causes of Death Register. 2008 (cited; available from: http://www.socialstyrelsen. se/en/Statistics/statsbysubject/The- Cause-of-Death- Register.htm).
16. Edberg A, Forsberg L, Jacobsson A, Nyqvist K. The National Patient Register. 2008 (cited; available from: http://www.socialstyrelsen.se/en/ Statistics/statsby subject/The+Swedish+Hospital+Discharge+Register. htm).
17. Drevenhorn E, Hakansson A, Petersson K. Blood pressure measurement-an observational study of 21 public health nurses. J Clin Nurs 2001; 10(2): 189-194.
18. Profdoc Software. 2008 (cited; Medical Office) Available from: http://www.profdoc.com/medical-office/software/.
19. Lidman B, Linder R. Working Model. 2007 (cited; available from: http://www.pygargus.se/3-en.html).
20. Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin DD, Jonsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005; 12(6): 530-534.
21. Ringborg A, Martinell M, Stalhammar J, Yin DD, Lindgren P. Resource use and costs of type 2 diabetes in Sweden-estimates from population-based register data. Int J Clin Pract 2008; 62(5): 708-716.
22. Ringborg A, Lindgren P, Martinell M, Yin DD, Schon S, Stalhammar J. Prevalence and incidence of Type 2 diabetes and its complications 1996-2003-estimates from a Swedish population-based study. Diabet Med 2008; 25(10): 1178-1186.
23. Team RDC. R: A Language and Environment for Statistical Computing. Fountation for Statistical Computing: Vienna Austria, 2008.
24. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26(4): 819-824.
25. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.NEngl J Med 2008; 359(21): 2195-2207.
26. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362(9386): 767-771.
27. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE trial). Am J Cardiol 2008; 101(5): 634-638.
28. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93(11): 1432-1435, A1410.
29. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366(9496): 1545-1553.
30. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7(1): 53-59.
31. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/losartan study investigators. Am J Hypertens 1999; 12(12 Pt 1-2): 1181-1187.
32. Okin PM, Devereux RB, Hille DA, Kjeldsen S, Lindholm LH, Edelman JM et al. Concomitant hydrochlorothiazide therapy in hypertensive patients is associated with reduced cardiovascular morbidity and mortality independent of blood pressure and electrocardiographic left ventricular hypertrophy: the LIFE study. Circulation 2008; 118(18): 886.